Anzeige
Mehr »
Samstag, 22.11.2025 - Börsentäglich über 12.000 News
ActiveVoices: Warum Investoren hinschauen - und welches Telekom-Upside denkbar ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P4H | ISIN: SE0023261292 | Ticker-Symbol: 5JD0
Frankfurt
21.11.25 | 08:04
1,524 Euro
+1,06 % +0,016
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EXPRES2ION BIOTECH HOLDING AB Chart 1 Jahr
5-Tage-Chart
EXPRES2ION BIOTECH HOLDING AB 5-Tage-Chart

Aktuelle News zur EXPRES2ION BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.11.ExpreS2ion Biotech Holding AB Q3 Loss Drops-
13.11.ExpreS2ion Biotech steigert Einkünfte um 36 % - Aktie reagiert mit Kursplus1
13.11.ExpreS2ion Biotech Holding AB: ExpreS2ion Announces Financial Results for the First Nine Months and Third Quarter of 2025168Hørsholm, Denmark, 13 November 2025 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its first nine months and third quarter 2025 results. The report is available as an attachment and...
► Artikel lesen
12.11.ExpreS2ion And Serum Institute Of India Reach Licensing Deal For Malaria Vaccines1
12.11.EXPRES2ION BIOTECH HOLDING AB: Correction: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines2
12.11.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines1
10.11.EXPRES2ION BIOTECH HOLDING AB: Oxford-Led Malaria Vaccine Trials Using ExpreS2ion Platform Advance Through Clinical Phases17
EXPRES2ION BIOTECH Aktie jetzt für 0€ handeln
07.11.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Hereby Changes Certified Advisor to Redeye2
03.11.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion to Participate in Key Investor and Industry Events in November 20254
08.10.EXPRES2ION BIOTECH HOLDING AB: VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase1
06.10.EXPRES2ION BIOTECH HOLDING AB: Warrants of Series TO 11 Were Exercised to Approximately 88.5 Percent, ExpreS2ion Receives Approximately SEK 10.4 Million and Resolves on Directed Issues to Guarantors2
15.09.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Obtains Top Guarantee Commitments and Subscription Commitments for Warrant Program TO 11, Reflecting Continued Support and Reinforcing Funding2
12.09.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Announces TO 11 Warrant Exercise Price and Start of Exercise Period19
12.09.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion to Present in Upcoming Investor Events2
04.09.ExpreS2ion Biotech Holding AB: ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial144Hørsholm, Denmark, 4 September 2025 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine...
► Artikel lesen
02.09.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events2
27.08.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Biotech Announces Analysguiden Publishes Updated Equity Research Report; Price Target Maintained at SEK 755
21.08.ExpreS2ion Biotech Holding AB: ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 303114Hørsholm, Denmark, 21 August 2025 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion" or the "Company") is pleased to announce that Pareto Securities has published...
► Artikel lesen
21.08.ExpreS2ion Biotech Holding AB: ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025483Hørsholm, Denmark, 21 August 2025 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its half-year and second quarter 2025 results. The report is available as an attachment and on ExpreS2ion's...
► Artikel lesen
18.07.ExpreS2ion Biotech Holding AB: ExpreS2ion Highlights Strategic Relevance of GHIT-Funded Malaria Vaccine Development Through Ownership in AdaptVac338Hørsholm, Denmark, 18 July 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2, "ExpreS2ion" or the "Company"), a clinical-stage biotechnology company with a focused portfolio...
► Artikel lesen
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1